Pyrrolidine-based 3-deoxysphingosylphosphorylcholine analogs as possible candidates against neglected tropical diseases (NTDs): identification of hit compounds towards development of potential treatment of Leishmania donovani
Open Access
- 1 January 2021
- journal article
- research article
- Published by Taylor & Francis in Journal of Enzyme Inhibition and Medicinal Chemistry
- Vol. 36 (1) , 1922-1930
Abstract
A rational-based process was adopted for repurposing pyrrolidine-based 3-deoxysphingosylphosphorylcholine analogs bearing variable acyl chains, different stereochemical configuration and/or positional relationships. Structural features were highly influential on activity. Amongst, enantiomer 1e having 1,2-vicinal relationship for the -CH2O- and the N-acyl moieties, a saturated palmitoyl chain and an opposite stereochemical configuration to natural sphingolipids was the most potent hit compound against promastigotes showing IC50 value of 28.32 µM. The corresponding enantiomer 1a was 2-fold less potent showing a eudismic ratio of 0.54 in promastigotes. Compounds 1a and 1e inhibited the growth of amastigotes more potently relative to promastigotes. Amongst, enantiomer 1a as the more selective and safer. In silico docking study using a homology model of Leishmania donovani inositol phosphoceramide synthase (IPCS) provided plausible reasoning for the molecular factors underlying the found activity. Collectively, this study suggests compounds 1a and 1e as potential hit compounds for further development of new antileishmanial agents.Keywords
Funding Information
- National Research Foundation of Korea (MSIT, NRF-2017M3A9G6068246)
This publication has 31 references indexed in Scilit:
- Drug repurposing and human parasitic protozoan diseasesInternational Journal for Parasitology: Drugs and Drug Resistance, 2014
- Asymptomatic Leishmania Infection: A New Challenge for Leishmania ControlClinical Infectious Diseases, 2014
- Validation of a simple resazurin-based promastigote assay for the routine monitoring of miltefosine susceptibility in clinical isolates of Leishmania donovaniParasitology Research, 2012
- NCATS launches drug repurposing programNature Biotechnology, 2012
- In Vitro and In Vivo Efficacy of Ether Lipid Edelfosine against Leishmania spp. and SbV-Resistant ParasitesPLOS Neglected Tropical Diseases, 2012
- Exploring Leishmania major Inositol Phosphorylceramide Synthase (LmjIPCS): Insights into the ceramide binding domainOrganic & Biomolecular Chemistry, 2011
- Phospholipid and sphingolipid metabolism in LeishmaniaMolecular and Biochemical Parasitology, 2010
- Leishmaniasis and povertyTrends in Parasitology, 2006
- The Protozoan Inositol Phosphorylceramide SynthaseJournal of Biological Chemistry, 2006
- Drug repositioning: identifying and developing new uses for existing drugsNature Reviews Drug Discovery, 2004